Navigation Links
Vanda Pharmaceuticals Reports First Quarter 2011 Results
Date:5/5/2011

ROCKVILLE, Md., May 5, 2011 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced financial and operational results for the first quarter ended March 31, 2011.

"We are very excited about the significant progress we have made to date in 2011," said Mihael H. Polymeropoulos, M.D., President and Chief Executive Officer. "Our first product, Fanapt®, which is marketed in the U.S. for the treatment of schizophrenia has now entered a Phase I study to evaluate the safety and pharmacokinetic profiles of two different long-acting formulations in patients with schizophrenia.  In addition, we have expanded the tasimelteon clinical program with a Phase IIb/III Study in Major Depression that will begin in the second half of 2011."

Key Highlights:

  • Vanda recorded first quarter 2011 revenue of $7.5 million including royalties of $0.9 million. Fanapt® prescriptions, as reported by IMS, reached 25,000 in the first quarter of 2011.
  • Fanapt® long-acting injectable (depot) formulation advanced into clinical studies.
  • European filing for oral Fanapt® is targeted for the second half of 2011.
  • Tasimelteon program expanded to include a Phase IIb/III study in patients with Major Depressive Disorder.   Study expected to begin in the second half of 2011.
  • The European Commission (EC) granted orphan drug designation for tasimelteon for Non-24-Hour Sleep/Wake Disorder (N24HSWD.)  
  • Top-line efficacy results for tasimelteon for N24HSWD are expected in mid 2012; NDA submission planned for the first half of 2013.

  • FIRST QUARTER 2011 REPORTED RESULTSTotal revenues for the first quarter of 2011 were $7.5 million, com
    '/>"/>

    SOURCE Vanda Pharmaceuticals Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related biology technology :

    1. Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
    2. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
    3. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results
    4. Vanda Pharmaceuticals Reports First Quarter 2009 Results
    5. Vanda Pharmaceuticals to Present Data on Fanapt(TM) and Tasimelteon at the 162nd American Psychiatric Association Annual Meeting
    6. Vanda Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 10, 2009
    7. Vanda Pharmaceuticals Reports Second Quarter 2009 Results
    8. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results
    9. Vanda Pharmaceuticals to Announce Second Quarter 2010 Financial Results on August 5, 2010
    10. Vanda Pharmaceuticals to Announce Fourth Quarter 2010 Financial Results on February 10, 2011
    11. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/11/2014)... -- EPFL and the University of  Geneva ... John P. Donoghue . The American neuroscientist is to ... The new Wyss Center for Bio- and ... , has named as its director one of ... , founder of Brown University,s Institute for Brain Science, ...
    (Date:7/10/2014)... 2014 Product and process impurities ... abundance and are often “lost in the noise,” ... Join presenters Dr. Rowel Tobias, Senior Scientist, Protein ... Head of Quality at Nanotherapeutics, Inc., to lear ... speed detection and quantitation while achieving the required ...
    (Date:7/10/2014)... (PRWEB) July 10, 2014 Robert Harman, DVM, ... Medicine company, is proud to announce the relaunch of his ... with a new series called “ What are Stem Cells ... an honest and straightforward foundation in the basics of stem ... decision on the right type of treatment when considering regenerative ...
    (Date:7/10/2014)... July 10, 2014 On July ... Medvedev , presented Russia,s first ... . The Company is developing a unique project called ... BIOCAD develops a number of innovative drugs based on ... The ceremony took place at the International Exhibition "Innoprom ...
    Breaking Biology Technology:John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 2John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 3Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2
    ... Novavax, Inc. (Nasdaq: NVAX ) a clinical-stage vaccine company, ... Annual Health Care Conference 2009 on December 2, 2009 at 12:30 ... Novavax will provide an overview of the company,s business strategy, research ... live audio only presentation can be accessed via the Company website ...
    ... 30 Dr. Jessica Torrente, Assistant Professor of Radiology ... demonstrated the integration and use of Breast-Specific Gamma Imaging ... for the diagnosis of breast cancer today at the ... (RSNA). , "The purpose of the exhibit was to ...
    ... 30 BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) ... has granted orphan drug designation for 3,4-diaminopyridine (3,4-DAP), amifampridine ... Syndrome (LEMS). 3,4-DAP has previously received orphan drug ... the Committee for Medicinal Products for Human Use of ...
    Cached Biology Technology:NOVAVAX to Present at the Piper Jaffray 21st Annual Health Care Conference 2Breast-Specific Gamma Imaging In Clinical Practice as an Adjunct Imaging Modality for Diagnosis of Breast Cancer 2FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 2FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 3FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 4
    (Date:7/11/2014)... international team of researchers, including scientists from the Max ... a reported a major step in understanding photosynthesis, the ... maintains the oxygen in its atmosphere and which is ... earth. , The researchers report the first direct ... namely the step in which a specific protein complex, ...
    (Date:7/11/2014)... of kidney injury related to the use of hydroxyethyl ... HES molecules, according to a report in Anesthesia ... Research Society (IARS). , The "total mass of HES ... human renal proximal tubule cells (PTCs), concludes the laboratory ... Hospital Wrzburg, Austria. Other factorssuch as differences in ...
    (Date:7/11/2014)... normal circumstances, astrocytes participate in normal physiological ... exhibit therapeutic and repairing effects on brain ... found that nerve cells differentiated from adipose-derived ... viability, which produces influences on subsequent studies ... Hospital, Hebei United University, China demonstrated that ...
    Breaking Biology News(10 mins):A first direct glimpse of photosynthesis in action 2In lab studies, hydroxyethyl starch has direct harmful effects on kidney cells 2
    ... in the equatorial Pacific by the end of the century, ... study shows that climate change could cause ocean currents to ... of islands right on the equator. Those islands include ... of Kiribati. This low-lying country is at risk from sea-level ...
    ... New research published online in the FASEB ... 5-lipoxygenase, plays a key role in cell death induced ... likely help prevent or lessen the severity of immune ... space conditions initiate health problems that mimic the aging ...
    ... going on in DPR Korea than rocket science: local people ... their food supply through agroforestry. This is according to a ... How participatory agroforestry restored land and secured the food supply ... that in DPR Korea a bottomup participatory process of developing ...
    Cached Biology News:Global warming refuge discovered near at-risk Pacific island nation of Kiribati 2Global warming refuge discovered near at-risk Pacific island nation of Kiribati 3Global warming refuge discovered near at-risk Pacific island nation of Kiribati 4Scientists discover enzyme that could slow part of the aging process in astronauts -- and the elderly 2Agroforestry is not rocket science but it might save DPR Korea 2Agroforestry is not rocket science but it might save DPR Korea 3
    ... [RS17 ] to PRKAR2 cAMP is ... of cellular functions. cAMP exerts its effects ... which transduces the signal through phosphorylation of ... AMPK is a tetramer composed of two ...
    The large Dodeca stainer shaking rack holds the staining trays in the large Dodeca stainer....
    ...
    ...
    Biology Products: